11β,13-Dihydrolactucopicrin
11β,13-Dihydrolactucopicrin is a sesquiterpene lactone and the main bitter component of chicory root. 11β,13-Dihydrolactucopicrin inhibits yeast α-glucosidase activity (IC50 = 27.49 μM) and inhibits Crz1 activation and nuclear accumulation. 1β,13-Dihydrolactucopicrin possesses blood-brain barrier penetration capacity in an in vitro HBMEC blood-brain barrier model and can generate cysteine-conjugated metabolites within brain microvascular endothelial cells. 11β,13-Dihydrolactucopicrin can regulate the lncRNA H19/miR-21-3p signaling axis; it upregulates the expression of ABCG2 and lncRNA H19, downregulates miR-21-3p, inhibits the release of IL-6, TNF-α, and hs-CRP pro-inflammatory mediators, and alleviates urate-induced inflammatory injury in renal epithelial cells. 11β,13-Dihydrolactucopicrin can be used in research on diabetes and renal urate deposition.
For research use only. We do not sell to patients.
- CAS No.: 125519-47-3
- Formula: C23H24O7
- Molecular Weight:412.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
|
α‑glucosidase 27.49 μM (IC50) |
IL-6 |
TNF-α |
In Vitro
11β,13-dihydrolactucopicrin (12.5-100 μM; 3 h) has a maximum non-toxic concentration of 12.5 µM in Saccharomyces cerevisiae[1].
11β,13-dihydrolactucopicrin exhibited moderate inhibitory activity against the calcineurin-Crz1 pathway in Saccharomyces cerevisiae YAA5, with an inhibition rate of 26% at 12.5 µM[1].
11β,13-Dihydrolactucopicrin (compound 5) inhibited yeast α-glucosidase with an IC50 of 27.49 μM, showing limited inhibitory activity, possibly because its phenyl group hinders binding to the enzyme[2].
11β,13-Dihydrolactucopicrin (predicted by molecular docking) showed good binding activity with the ABCG2 protein, exhibiting the lowest binding energy among the tested compounds[3].
11β,13-dihydrolactucopicrin (5 μM; 2 h) can be transported across the in vitro BBB model of HBMEC, with a transport percentage between 10% and 20%[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NRK-52E
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Significantly suppressed IL-6 levels.
Significantly decreased hs-CRP levels.
Upregulated ABCG2 protein expression.
Elevated ABCG2 mRNA expression.
Uniquely and significantly upregulated lncRNA H19 expression.
Markedly downregulated miR-21-3p expression.
-
Cell Line:NRK-52E
-
Concentration:10, 50, 100, 200, 500 μM
-
Incubation Time:24 h
-
Result:Assessed viability of NRK-52E cells to determine appropriate non-cytotoxic concentrations for subsequent experiments.
Chemical Information
-
CAS No. 125519-47-3
-
Molecular Weight 412.44
-
Formula C23H24O7
-
SMILES
C(O)C=1[C@@]2([C@@]3([C@@]([C@@H](OC(CC4=CC=C(O)C=C4)=O)CC(C)=C2C(=O)C1)([C@H](C)C(=O)O3)[H])[H])[H]
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
11β,13-Dihydrolactucopicrin Related Classifications
HY-N9932 Related Classifications
Powered by Bioz